150 related articles for article (PubMed ID: 37748098)
21. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
Front Immunol; 2020; 11():594271. PubMed ID: 33224149
[TBL] [Abstract][Full Text] [Related]
22. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
Saikali S; Avril T; Collet B; Hamlat A; Bansard JY; Drenou B; Guegan Y; Quillien V
J Neurooncol; 2007 Jan; 81(2):139-48. PubMed ID: 17004103
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.
Yin Y; Boesteanu AC; Binder ZA; Xu C; Reid RA; Rodriguez JL; Cook DR; Thokala R; Blouch K; McGettigan-Croce B; Zhang L; Konradt C; Cogdill AP; Panjwani MK; Jiang S; Migliorini D; Dahmane N; Posey AD; June CH; Mason NJ; Lin Z; O'Rourke DM; Johnson LA
Mol Ther Oncolytics; 2018 Dec; 11():20-38. PubMed ID: 30306125
[TBL] [Abstract][Full Text] [Related]
24. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
25. IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas.
Killock D
Nat Rev Clin Oncol; 2024 May; 21(5):335. PubMed ID: 38514882
[No Abstract] [Full Text] [Related]
26. Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.
Newman JP; Wang GY; Arima K; Guan SP; Waters MR; Cavenee WK; Pan E; Aliwarga E; Chong ST; Kok CYL; Endaya BB; Habib AA; Horibe T; Ng WH; Ho IAW; Hui KM; Kordula T; Lam PYP
Nat Commun; 2017 Dec; 8(1):1913. PubMed ID: 29203859
[TBL] [Abstract][Full Text] [Related]
27. An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts.
Pandya H; Gibo DM; Garg S; Kridel S; Debinski W
Neuro Oncol; 2012 Jan; 14(1):6-18. PubMed ID: 21946118
[TBL] [Abstract][Full Text] [Related]
28. In Vitro Screening Assay for Activators of T-Cell Migration to Solid Tumors.
Dey A; Sharp DJ
Methods Mol Biol; 2022; 2423():109-113. PubMed ID: 34978693
[TBL] [Abstract][Full Text] [Related]
29. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.
Brown CE; Hibbard JC; Alizadeh D; Blanchard MS; Natri HM; Wang D; Ostberg JR; Aguilar B; Wagner JR; Paul JA; Starr R; Wong RA; Chen W; Shulkin N; Aftabizadeh M; Filippov A; Chaudhry A; Ressler JA; Kilpatrick J; Myers-McNamara P; Chen M; Wang LD; Rockne RC; Georges J; Portnow J; Barish ME; D'Apuzzo M; Banovich NE; Forman SJ; Badie B
Nat Med; 2024 Apr; 30(4):1001-1012. PubMed ID: 38454126
[TBL] [Abstract][Full Text] [Related]
30. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.
Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W
Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737
[TBL] [Abstract][Full Text] [Related]
31. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
33. Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.
Kashyap D; Salman H
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612592
[TBL] [Abstract][Full Text] [Related]
34. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma.
Schmidts A; Srivastava AA; Ramapriyan R; Bailey SR; Bouffard AA; Cahill DP; Carter BS; Curry WT; Dunn GP; Frigault MJ; Gerstner ER; Ghannam JY; Kann MC; Larson RC; Leick MB; Nahed BV; Richardson LG; Scarfò I; Sun J; Wakimoto H; Maus MV; Choi BD
Neurooncol Adv; 2023; 5(1):vdac185. PubMed ID: 36751672
[TBL] [Abstract][Full Text] [Related]
35. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
[TBL] [Abstract][Full Text] [Related]
36. Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma.
Meister H; Look T; Roth P; Pascolo S; Sahin U; Lee S; Hale BD; Snijder B; Regli L; Ravi VM; Heiland DH; Sentman CL; Weller M; Weiss T
Clin Cancer Res; 2022 Nov; 28(21):4747-4756. PubMed ID: 36037304
[TBL] [Abstract][Full Text] [Related]
37. Characterization of Chimeric Antigen Receptor Modified T Cells Expressing scFv-IL-13Rα2 after Radiolabeling with 89Zirconium Oxine for PET Imaging.
Leland P; Kumar D; Nimaggada S; Bauer SR; Puri RK; Joshi BH
Res Sq; 2023 Jan; ():. PubMed ID: 36711796
[TBL] [Abstract][Full Text] [Related]
38. Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas.
Bozinov O; Kalk JM; Krayenbühl N; Woernle CM; Sure U; Bertalanffy H
Neurol Med Chir (Tokyo); 2010; 50(8):617-21. PubMed ID: 20805641
[TBL] [Abstract][Full Text] [Related]
39. Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma.
Sakunrangsit N; Khuisangeam N; Inthanachai T; Yodsurang V; Taechawattananant P; Suppipat K; Tawinwung S
Cancer Immunol Immunother; 2024 Apr; 73(6):98. PubMed ID: 38619641
[TBL] [Abstract][Full Text] [Related]
40. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.
Kang CH; Kim Y; Lee SM; Choi SU; Park CH
Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
